2 Information about siponimod

Marketing authorisation indication

2.1 Siponimod (Mayzent, Novartis) is indicated for 'the treatment of adult patients with secondary progressive multiple sclerosis with active disease evidenced by relapses or imaging features of inflammatory activity'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.


2.3 The list price for siponimod is £1,643.72 per pack of 28×2‑mg tablets (excluding VAT; BNF online, September 2020).

2.4 The company has a commercial arrangement with the NHS. This makes siponimod available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)